An observational study in Diabetes Mellitus, Type 2 and Diabetic Cardiomyopathies, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by University of Leicester · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Diabetes Mellitus, Type 2 by University of Leicester — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Leicester.
Among the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2017, is one of 11 observational ones, and was the 10th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester are open now, in 1 country. Recruiting first, the newest first:
University of Leicester · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Leicester · Sites in United Kingdom
Ages 18–75
University of Leicester · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Leicester · Sites in United Kingdom
Ages 18–75
University of Leicester
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2 · Phase 4 4
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 593 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 44 across the 12 interventional studies, 241 across the 11 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 2 by University of Leicester that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06652763University of LeicesterManganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Diabetes Mellitus, Type 2 by University of Leicester, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background: Heart failure is a major cause of morbidity and mortality in diabetes mellitus, but its pathophysiology is poorly understood.
Aim: To determine the prevalence and determinants of subclinical cardiovascular dysfunction in adults with type 2 diabetes (T2D).
Plan: 518 asymptomatic adults (aged 18-75 years) with T2D will undergo comprehensive evaluation of cardiac structure and function using cardiac MRI (CMR) and spectroscopy, echocardiography, CT coronary calcium scoring, exercise tolerance testing and blood sampling. 75 controls will undergo the same evaluation.
Primary hypothesis: myocardial steatosis is an independent predictor of left ventricular global longitudinal strain. Secondary hypotheses: will assess whether CMR is more sensitive to detect early cardiac dysfunction than echocardiography and BNP, and whether cardiac dysfunction is related to peak oxygen consumption.
Expected value of results: This study will reveal the prevalence and determinants of cardiac dysfunction in T2D, and could provide targets for novel therapies.
Cases will be adults with stable type 2 diabetes and no past medical history of known cardiovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Importantly, patients with subclinical CAD, and other common comorbidities such as obesity and hypertension, will not be excluded from this study. This will enable us to evaluate the contribution of CAD to myocardial dysfunction in diabetes and ensures our study group is representative of the general population with diabetes. Similarly, as mild dyspnoea is extremely common and non-specific participants with mild dyspnoea will be included.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be aged (≥18 and ≤75 years) with T2D and no prior history of cardiovascular disease.
Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy · Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: Computed tomography coronary artery calcium scoring · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) · Diagnostic Test: Ambulatory blood pressure monitoring · Diagnostic Test: Accelerometer watch · Diagnostic Test: Blood tests
Cases will be compared with age-, gender- and ethnicity-matched healthy controls.
Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy · Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: Computed tomography coronary artery calcium scoring · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Manganese-enhanced magnetic resonance imaging (MEMRI) · Diagnostic Test: Ambulatory blood pressure monitoring · Diagnostic Test: Accelerometer watch · Diagnostic Test: Blood tests
CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue.
Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden in addition to epicardial adipose tissue characterisation and systolic strain.
Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
A subset of the participants will have cardiac MRI scanning with manganese-based contrast agent, lasting approximately 45-50 minutes. After localisers, baseline functions and native T1 maps have been acquired, Mangafodipir (0.1mL/kg) will be administered intravenously at 1ml/min, with additional T1 maps acquired every 2.5 min after administration of the contrast agent for up to 30 minutes.
A 24-hour blood pressure monitor will be worn at the end of the visit to the following day.
Watch worn to collect free living physical activity data for 7 days.
Collection of blood samples from each participant to characterise the participant's health status and to develop a proteomic signature of early heart failure.
Prevalence of early heart failure in type 2 diabetes
Proportion of participants with type 2 diabetes who have features of early heart failure
Time frame: 5 years
Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes
Multivariate and independent predictors of LV systolic and diastolic function in type 2 diabetes
Time frame: 3 years
Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes
Sensitivity of CMR versus echocardiography and BNP for detecting subclinical cardiovascular dysfunction in type 2 diabetes
Time frame: 3 years
Independent association of CMR measures with aerobic exercise capacity in type 2 diabetes
Independent association of CMR measures (LV systolic and diastolic strain and strain rates) with aerobic exercise capacity (peak VO2) in type 2 diabetes
Time frame: 3 years
Differences in LV remodelling (indexed LV mass) between cases and controls
Differences in LV remodelling (indexed LV mass) between cases and controls
Time frame: 3 years
Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes
Independent clinical and imaging predictors of major adverse cardiovascular and, in particular, heart failure events in the patients with type 2 diabetes
Time frame: 5 years
Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls.
Differences in cardiac MRI and echo-derived systolic and diastolic strain and strain rates between cases and controls.
Time frame: 3 years
Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls
Differences in coronary atheroma burden (CT coronary artery calcium score) between cases and controls
Time frame: 3 years
Differences in aerobic exercise capacity (peak V02) between cases and controls
Differences in aerobic exercise capacity (peak V02) between cases and controls
Time frame: 3 years
Differences in myocardial perfusion reserve between cases and controls
Differences in myocardial perfusion reserve between cases and controls
Time frame: 3 years
Differences in heart rate and blood pressure variability between cases and controls
Differences in heart rate and blood pressure variability between cases and controls
Time frame: 3 years
Myocardial steatosis
Myocardial steatosis as an independent predictor of LV global longitudinal strain
Time frame: 3 years
Myocardial calcium handling as assessed by manganese-enhanced magnetic resonance imaging (MEMRI)
Manganese influx constants calculated using Patlak modelling
Time frame: 5 years
Proteomic signature
Proteomic analysis will be conducted to identify a proteomic signature of early heart failure in type 2 diabetes that will be externally validated
Time frame: 5 years
Remission of type 2 diabetes
The phenotype of participants defined as in remission will be compared to active type 2 diabetes and healthy volunteers
Time frame: 5 years
Plan to share: No
Started Oct 2017 (actual). Primary completion is estimated for Oct 2029, 144 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.